Editas Medicine (8EM) Price & Analysis

2 Followers

8EM Stock Chart & Stats

€2.72

-€0.06(-2.61%)

At close: Jul 29 4:00 PM EDT

€2.72

-€0.06(-2.61%)

Day’s Range― - ―

52-Week Range€1.38 - €3.66

Previous CloseN/A

Volume0.00

Average Volume (3M)443.00

Market Cap

€397.21M

Enterprise Value€246.12M

Total Cash (Recent Filing)€211.65M

Total Debt (Recent Filing)€15.51M

Price to Earnings (P/E)―

Beta1.54

Next Earnings

Nov 09, 2026

EPS Estimate

-0.17

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.75

Shares Outstanding153,580,030

10 Day Avg. Volume1,159

30 Day Avg. Volume443

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)6.67

Price to Sales (P/S)4.49

P/FCF Ratio-1.10

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€5.06

Price Target Upside85.88% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering8

EPS Forecast (FY)-0.69

Revenue Forecast (FY)€22.98M

Bulls Say, Bears Say

Bulls Say

Improving Revenue And Gross MarginRevenue growth alongside positive gross margin indicates improving commercial and operating fundamentals despite the company remaining development-stage. If sustained, this combination can support greater funding capacity for research, strengthen the platform’s economics, and improve future earnings potential.

De-risked Balance SheetSharp debt reduction and rebuilt equity improve financial flexibility and reduce leverage-related pressure. This gives Editas more capacity to manage development programs through volatility, although continued cash discipline remains important because the company is not yet profitable.

EDIT-401 Clinical AdvancementRegulatory clearance to begin Strive converts EDIT-401 from preclinical development into human testing for a genetically defined cardiovascular condition. The trial creates identifiable clinical milestones and provides a pathway to validate Editas’s in vivo editing platform over the next several quarters.

Bears Say

Persistent UnprofitabilityDeep losses show that current revenue is insufficient to cover research, development, and operating costs. Continued unprofitability can constrain internal reinvestment, increase dependence on financing decisions, and leave results highly sensitive to the timing and outcome of clinical programs.

Structurally Negative Cash FlowLarge ongoing cash outflows indicate that Editas is funding research and operations well ahead of profitability. Even with moderated burn, sustained negative free cash flow requires careful runway management and may force reliance on external funding or existing reserves to maintain development.

No Recurring Product-sales BaseThe absence of an established commercial product base means revenue depends primarily on collaborations, licensing payments, and milestone events rather than recurring sales. That model can produce uneven funding and leaves durable revenue growth dependent on successful clinical and commercial execution.

Editas Medicine News

Wells Fargo upgrades Editas Medicine after EDIT-401 study gets green light

As previously reported, Wells Fargo upgraded Editas Medicine (EDIT) to Overweight from Equal Weight with a price target...

4d ago

EDIT

Editas Medicine upgraded to Overweight from Equal Weight at Wells Fargo

Wells Fargo upgraded Editas Medicine (EDIT) to Overweight from Equal Weight with a $6 price target Published first...

4d ago

EDIT

Editas Medicine receives approval to initiate clinical trial of EDIT-401

Editas Medicine (EDIT) announced it has received approval to initiate the Phase 1/2 Strive clinical trial of EDIT-401...

4d ago

EDIT

Editas slips amid pressure on gene-editing sector after Anthropic update

Editas Medicine (EDIT) is trading lower alongside other gene editing peers after Anthropic shared early findings on a...

19d ago

EDIT

Microsoft upgraded, HubSpot initiated: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

19d ago

ALV

ARX

Editas Medicine upgraded to Buy at Guggenheim on EDIT-401 potential

As previously reported, Guggenheim upgraded Editas Medicine (EDIT) to Buy from Neutral with a $5 price target Should...

19d ago

EDIT

Editas Medicine upgraded to Buy from Neutral at Guggenheim

Guggenheim upgraded Editas Medicine (EDIT) to Buy from Neutral with a $5 price target Published first on TheFly...

19d ago

EDIT

Editas wins approval to launch EDIT-401 Strive trial

The latest announcement is out from Editas Medicine ( ($EDIT) ). On October 8, 2026, Editas Medicine said...

4d ago

EDIT

Editas, Sagimet, Dropbox, Arcturus, Quanta Trending With Analysts

Analysts are intrested in these 5 stocks: ( ($EDIT) ), ( ($SGMT) ), ( ($DBX) ), ( ($ARCT)...

16d ago

DBX

PWR

Editas Medicine appoints Dan Ory as chief medical officer

Editas Medicine (EDIT) announced the appointment of Dan Ory as chief medical officer, effective immediately. Ory will oversee...

1M ago

EDIT

Editas Medicine files $400M mixed securities shelf

16:27 EDT Editas Medicine (EDIT) files $400M mixed securities shelf Published first on TheFly – the ultimate source...

1M ago

EDIT

Editas Medicine initiated with a Buy at Ladenburg

Ladenburg initiated coverage of Editas Medicine (EDIT) with a Buy rating and $6 price target Published first on...

2M ago

EDIT

Phil Nadeau Reiterates Buy on Editas Medicine, Citing Strong Cash Runway and Upcoming EDIT-401 Clinical Catalyst

TD Cowen analyst Phil Nadeau has maintained their bullish stance on EDIT stock, giving a Buy rating yesterday....

2M ago

EDIT

Editas Medicine Strengthens Board With New Cardiology Director

An announcement from Editas Medicine ( ($EDIT) ) is now available. On August 3, 2026, Editas Medicine director...

2M ago

EDIT

8EM FAQ

What was Editas Medicine Inc’s price range in the past 12 months?

Editas Medicine Inc lowest stock price was €1.38 and its highest was €3.66 in the past 12 months.

What is Editas Medicine Inc’s market cap?

Editas Medicine Inc’s market cap is €397.21M.

When is Editas Medicine Inc’s upcoming earnings report date?

Editas Medicine Inc’s upcoming earnings report date is Nov 09, 2026 which is in 28 days.

How were Editas Medicine Inc’s earnings last quarter?

Editas Medicine Inc released its earnings results on Aug 05, 2026. The company reported -€0.134 earnings per share for the quarter, beating the consensus estimate of -€0.242 by €0.108.

Is Editas Medicine Inc overvalued?

According to Wall Street analysts Editas Medicine Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Editas Medicine Inc pay dividends?

Editas Medicine Inc does not currently pay dividends.

What is Editas Medicine Inc’s EPS estimate?

Editas Medicine Inc’s EPS estimate is -0.17.

How many shares outstanding does Editas Medicine Inc have?

Editas Medicine Inc has 153,580,030 shares outstanding.

What happened to Editas Medicine Inc’s price movement after its last earnings report?

Editas Medicine Inc reported an EPS of -€0.134 in its last earnings report, beating expectations of -€0.242. Following the earnings report the stock price went up 8.468%.

Which hedge fund is a major shareholder of Editas Medicine Inc?

Currently, no hedge funds are holding shares in DE:8EM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Editas Medicine Stock Smart Score

Outperform

Fundamentals

Return on Equity

-196.63%

Trailing 12-Months

Asset Growth

12.72%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Editas Medicine (8EM) Earnings & Revenues

Historic Earnings Reports

8EM Stock 12 Month Forecast

Average Price Target

€5.06

▲(85.88% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","2":"€2","4":"€4","6":"€6","8":"€8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7.13775872,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€7.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.055912426666667,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€5.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.56887936,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€3.57</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2,4,6,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.26,2.635212209230769,3.0104244184615383,3.3856366276923078,3.760848836923077,4.136061046153846,4.511273255384616,4.886485464615385,5.261697673846154,5.636909883076923,6.012122092307692,6.387334301538462,6.762546510769231,{"y":7.13775872,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.26,2.4750701866666667,2.690140373333333,2.90521056,3.1202807466666664,3.3353509333333333,3.55042112,3.7654913066666666,3.980561493333333,4.19563168,4.410701866666667,4.625772053333334,4.840842240000001,{"y":5.055912426666667,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.26,2.3606830276923074,2.461366055384615,2.562049083076923,2.6627321107692308,2.7634151384615384,2.864098166153846,2.9647811938461537,3.0654642215384613,3.166147249230769,3.266830276923077,3.3675133046153842,3.4681963323076923,{"y":3.56887936,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.624,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.869,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.732,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.591,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.774,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.078,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.38,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.92,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.88,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.32,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.59,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.26,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >